Clinical use of inotropic therapy for heart failure: Looking backward or forward? Part I: Inotropic infusions during hospitalization

Circulation

Volumn 108, Issue 3, 2003, Pages 367-372

  Stevenson, Lynne Warner ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiomyopathy; Heart failure; Hemodynamics

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENYLATE CYCLASE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CALCIUM CHANNEL L TYPE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; GUANINE NUCLEOTIDE BINDING PROTEIN; INOTROPIC AGENT; LEVOSIMENDAN; METOLAZONE; MILRINONE; NESIRITIDE; NEUROHORMONE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; RYANODINE RECEPTOR; SODIUM CALCIUM EXCHANGE PROTEIN; TROPONIN I; UNINDEXED DRUG; VASOACTIVE AGENT; VASODILATOR AGENT;

ADRENERGIC STIMULATION; APOPTOSIS; CALCIUM CELL LEVEL; CLINICAL TRIAL; DISEASE COURSE; DIURESIS; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INDEX; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE PERFUSION; HEART OUTPUT; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY ISCHEMIA; MEDICAL DECISION MAKING; MORTALITY; OUTCOMES RESEARCH; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SYSTEMIC VASCULAR RESISTANCE; TREATMENT PLANNING; VASODILATATION;

CALCIUM CHANNELS, L-TYPE; CARDIOTONIC AGENTS; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; INPATIENTS; MYOCARDIAL CONTRACTION;

EID: 0042092537     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000078348.44634.BA     Document Type: Review

References (50)

1. Jarcho S. The Concept of Heart Failure. Cambridge, Mass: Harvard University Press; 1980:5-9.
2. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475.
3. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure: Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810-1816.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
6. Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319:80-86.
7. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001;142:393-401.
8. Lollgen H, Drexler H. Use of inotropes in the critical care setting. Crit Care Med. 1990;18:S56-S60.
9. Beregovich J, Bianchi C, Rubler S, et al. Dose-related hemodynamic and renal effects of dopamine in congestive heart failure. Am Heart J. 1974;87:550-557.
10. Goldberg LI. Dopamine: clinical uses of an endogenous catecholamine. N Engl J Med. 1974;291:707-710.
11. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure: mechanisms of action and recent clinical developments 2. N Engl J Med. 1986;314:349-358.
12. Lang RM, Fellner SK, Neumann A, et al. Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med. 1988;108:524-529.
13. Sonnenblick EH, Frishman WH, LeJemtel TH. Dobutamine: a new synthetic cardioactive sympathetic amine. N Engl J Med. 1979;300:17-22.
14. Colucci WS, Wright RF, Jaski BE, et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation. 1986;73:III-175-III-183.
15. Weinstein J, Baim DS. The effects of acute dobutamine administration on myocardial metabolism and energetics. Heart Failure. 1996;2:110-116.
16. Monrad ES, Baim DS, Smith HS, et al. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation. 1986;73:III-168-III-174.
17. Biddle TL, Benotti JR, Creager MA, et al. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol. 1987;59:1345-1350.
18. Maskin CS. Intermittent parenteral inotropic therapy in patients with chronic congestive heart failure: concept and clinical results. Heart Failure. 1986;2:117-122.
19. Tsvetkova TFD, Abraham WT, Kelly P, et al. Comparative hemodynamic effects of milrinone and dobutamine in heart failure patients treated chronically with carvedilol. J Card Fail. 1998;4(suppl 1):36. Abstract.
20. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994;330:1717-1722.
21. Connors AF Jr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients: SUPPORT Investigators. JAMA. 1996;276:889-897.
22. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med. 2003;348:5-14.
23. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287:628-640.
24. Grady KL, Dracup K, Kennedy G, et al. Team management of patients with heart failure: a statement for healthcare professionals from the Cardiovascular Nursing Council of the American Heart Association. Circulation. 2000;102:2443-2456.
25. Nohria A, Tsang S, Fang J, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797-1804.
26. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J. 1998;135: S293-S309.
27. Drazner MH, Hamilton MA, Fonarow G, et al. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant. 1999;18:1126-1132.
28. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
29. Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798-803.
30. Stevenson L, Bellil D, Grover-McKay M, et al. Effects of afterload reduction (diuretics and vasodilators) on left ventricular volume and mitral regurgitation in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1987;60:654-658.
31. Rosario LB, Stevenson LW, Solomon SD, et al. The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J Am Coll Cardiol. 1998;32:1819-1824.
32. Capomolla S, Pozzoli M, Opasich C, et al. Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function. Am Heart J. 1997;134:1089-1098.
33. Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol. 2002;39:1623-1629.
34. Pflugfelder PW, O'Neill BJ, Ogilvie RI, et al. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure. Can J Cardiol. 1991;7:5-10.
35. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547.
36. Zelis R, Flaim SF. Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis. 1982;24:437-459.
37. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138:285-290.
38. Hershberger R, Nauman D, Walker T, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail. 2003;9:180-187.
39. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136-141.
40. Levinoff Roth SN, Moe G. Intermittent intravenous amrinone infusion: a potentially cost effective mode of treatment of patients with refractory heart failure. Can J Cardiol. 1993;9:231-237.
41. Marius-Nunez AL, Heaney L, Fernandez RN, et al. Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J. 1996;132:805-808.
42. Unverferth DA, Blanford M, Kates RE, et al. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med. 1980;69:262-266.
43. Unverferth DV, Magorien RD, Altschuld R, et al. The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J. 1983;106:29-34.
44. Unverferth DV, Magorien RD, Lewis RP, et al. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J. 1980;100:622-630.
45. Likoff M, Weber KT, Andrews V. Amrinone in the treatment of chronic heart failure. J Am Coll Cardiol. 1984;3:1282-1290.
46. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure: Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
47. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
48. del Monte F, Hajjar R. Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol. 2003;546:49-61.
49. Hoshijima M, Ikeda Y, Iwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med. 2002;8:864-871.
50. del Monte F, Harding SE, Dec GW, et al. Targeting phospholamban by gene transfer in human heart failure. Circulation. 2002;105:904-907.